产业链观察2022-10-12 18:26
药闻| 2022年10月12日，$Sangamo Therapeutics(SGMO)$ 宣布了评估isaralgagene civaparvovec或ST-920的1/2期STAAR研究的最新初步临床数据，这是一种用于治疗法布里病的全资基因治疗候选产品，将于2022年10月12日在欧洲基因和细胞治疗协会（ESGCT）年度大会上发表.
| 今开：3.51 | 昨收：3.49 |
| 最高：3.55 | 最低：3.37 |
| 涨停价： | 跌停价： |
| 总市值：567844224 |
产业链观察2022-10-12 18:26
药闻| 2022年10月12日，$Sangamo Therapeutics(SGMO)$ 宣布了评估isaralgagene civaparvovec或ST-920的1/2期STAAR研究的最新初步临床数据，这是一种用于治疗法布里病的全资基因治疗候选产品，将于2022年10月12日在欧洲基因和细胞治疗协会（ESGCT）年度大会上发表.
Biotech笔记2022-08-21 21:24
CAR-T疗法使这一发现为癌症药物研究开辟了新的前沿。CAR-Treg是一种治疗类风湿性关节炎和1型糖尿病等自身免疫性疾病的新方法。该方法与CAR-T治疗核心的免疫细胞相比有不同的基因修饰，但目标相似。在过去的四年里，许多新成立的生物技术公司在开发这些治疗方法，称为调节性T细胞或“Treg”疗法。 <...
牛唐2022-01-07 11:09
$赛诺菲-安万特(SNY)$ 终止了和$Sangamo Therapeutics(SGMO)$ 的治疗SCD的基因疗法SAR445136合作，因为赛诺菲转向了universal genomic medicine。$Beam Therapeutics(BEAM)$
时光投资-Edward2021-11-05 08:13
2021年11月4日，Sangamo Therapeutics公司宣布，基因疗法isaralgagene civaparvovec（ST-920），在法布里病（Fabry disease）患者中进行的一项1/2期临床试验获得积极初步结果。试验结果显示，该疗法通常耐受性良好，并且将4名患者体内关键的α-半乳糖苷酶A （α-Gal A, 也称为AGA）的活性提高到高...
Sangamo Therapeutics(SGMO)01-25 03:06
$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001306550-23-003123 Act: 34 Size: 13 KB 网页链接
Sangamo Therapeutics(SGMO)2022-12-24 06:03
$Sangamo Therapeutics(SGMO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-22-311826 Act: 33 Size: 498 KB 网页链接
Sangamo Therapeutics(SGMO)2022-12-24 05:06
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001628280-22-032552 Act: 34 Size: 720 KB 网页链接
Sangamo Therapeutics(SGMO)2022-12-20 05:18
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 5.02, 5.03, and 9.01 Accession Number: 0001628280-22-032209 Act: 34 Size: 7 MB 网页链接
Sangamo Therapeutics(SGMO)2022-12-20 05:51
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-061951 Size: 7 KB 网页链接
Sangamo Therapeutics(SGMO)2022-12-20 06:06
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-061949 Size: 7 KB 网页链接
Sangamo Therapeutics(SGMO)01-25 03:06
$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001306550-23-003123 Act: 34 Size: 13 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-24 06:03
$Sangamo Therapeutics(SGMO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-22-311826 Act: 33 Size: 498 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-24 05:06
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001628280-22-032552 Act: 34 Size: 720 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-20 06:06
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-061949 Size: 7 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-20 05:51
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-061951 Size: 7 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-20 05:48
$Sangamo Therapeutics(SGMO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-22-061916 Size: 7 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-20 05:33
$Sangamo Therapeutics(SGMO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-22-061913 Size: 7 KB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-20 05:18
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 5.02, 5.03, and 9.01 Accession Number: 0001628280-22-032209 Act: 34 Size: 7 MB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-12-12 19:06
$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-22-031695 Act: 34 Size: 9 MB 网页链接查看全文
Sangamo Therapeutics(SGMO)2022-11-04 04:06
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001628280-22-028167 Act: 34 Size: 344 KB 网页链接查看全文
智通财经APP获悉，近期，RBC针对Verrica Pharmaceuticals(VRCA.US)、Sangamo Therapeutics(SGMO.US)、GooseHead Insurance(GSHD.US)三家公司发表研报，并强调了这三只股票未来强劲的长期增长前景，预计在未来一年的上行空间将至少达到50... 网页链接
$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001306550-23-003123 Act: 34 Size: 13 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-22-311826 Act: 33 Size: 498 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001628280-22-032552 Act: 34 Size: 720 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-061949 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-061951 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-22-061916 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-22-061913 Size: 7 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 5.02, 5.03, and 9.01 Accession Number: 0001628280-22-032209 Act: 34 Size: 7 MB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-22-031695 Act: 34 Size: 9 MB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001628280-22-028167 Act: 34 Size: 344 KB 网页链接